Skip to main content

Table 1 Demographics and clinical information

From: Relationship of cell-free urine MicroRNA with lupus nephritis in children

Features n of N (%) Mean (SD)
Lupus patients Controls Lupus Nephritis (LN),n, age (years) 14 18.33 ± 3.77
SLE without LN,n, age (years) 10 17.40 ± 2.59
Fibromyalgia 5
Juvenile Idiopathic Arthritis 5
Females   19 (79.1 %)
Race Black 13 (54.1 %)
  White 8 (33.4 %)
  Other° 3 (12.5 %)
Medications (SLE patients) Oral prednisone (mg/day) 24 (100 %) 26.1 (18.4)
Mycophenolate mofetil 10 (41.7 %)
Azathioprine 1 (4.1 %)
Cyclophosphamide 10 (41.7 %)
Diuretics 4 (16.6 %)
Angiotensin system blocking drug 12 (50 %)
LN Status (n = 14) GFR£ < 60 ml/min/m2 3 (21.4 %)  
Protein:creatinine ratio > 0.5 11 (78.6 %)  
Renal SLEDAI* score   5.6 (6.19)
Renal BILAG score   4.8 (4.54)
      Class 2 4 (28.6 %)  
ISN/RPS  Class 3 2 (14.3 %)
      Class 4 7 (50 %)
      Class 5 1 (7.1 %)
SLE Status (n = 24) Complement C3 low 9 (37.5 %)  
Complement C4 low 16 (66.7 %)
Presence of anti-dsDNA antibodies 18 (75 %)
  1. *Systemic Lupus Erythematosus Disease Activity Index, range 0–105; 0 – inactive LN
  2. ¶International Society for Nephrology Renal Pathology Society Class; there was no biopsy consistent with Class I or VI; °Other: includes Asians, Mixed race, Native Indian
  3. £GFR as estimated by the modified Schwartz formula